European urology · 2009
Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Draga Ronald O P, Grimbergen Matthijs C M, Kok Esther T, Jonges Trudy N, van Swol Christiaan F P, Bosch J L H Ruud
Аннотация
BACKGROUND: Photodynamic diagnosis (PDD) is a technique that enhances the detection of occult bladder tumors during cystoscopy using a fluorescent dye.
OBJECTIVE: To study the differential effects of bacillus Calmette-Guérin (BCG) and mitomycin C (MMC) intravesical therapy on the false-positive rate of PDD of bladder cancer.
DESIGN, SETTING, AND PARTICIPANTS: This study included 552 procedures and 1874 biopsies.
INTERVENTION: Tumors were resected and biopsies were taken from suspicious areas, under guidance of white-light endoscopy and 5-ALA (5-aminolevulinic acid)-induced fluorescence cystoscopy.
MEASUREMENTS: The influence of intravesical BCG immunotherapy and intravesical MMC chemotherapy on pyuria, inflammation, and PDD specificity was examined in univariate analyses.
RESULTS AND LIMITATIONS: BCG significantly results in inflammation (odds ratio [OR]: 1.53, p=0.002), leukocyturia (OR: 1.84, p=0.034), and false positives in PDD (OR: 1.49, p=0.001). However, a single BCG instillation within 3 mo before PDD is most likely not associated with increased false-positive rates (OR: 0.35, p=0.26). Leukocyturia normalizes within 6 wk after the last BCG instillation, but PDD specificity is reduced up to 3 mo.
CONCLUSIONS: BCG is an important predictor for false positives in PDD (5-ALA). More than one BCG instillation within 3 mo before fluorescence cystoscopy decreases the specificity of PDD.
OBJECTIVE: To study the differential effects of bacillus Calmette-Guérin (BCG) and mitomycin C (MMC) intravesical therapy on the false-positive rate of PDD of bladder cancer.
DESIGN, SETTING, AND PARTICIPANTS: This study included 552 procedures and 1874 biopsies.
INTERVENTION: Tumors were resected and biopsies were taken from suspicious areas, under guidance of white-light endoscopy and 5-ALA (5-aminolevulinic acid)-induced fluorescence cystoscopy.
MEASUREMENTS: The influence of intravesical BCG immunotherapy and intravesical MMC chemotherapy on pyuria, inflammation, and PDD specificity was examined in univariate analyses.
RESULTS AND LIMITATIONS: BCG significantly results in inflammation (odds ratio [OR]: 1.53, p=0.002), leukocyturia (OR: 1.84, p=0.034), and false positives in PDD (OR: 1.49, p=0.001). However, a single BCG instillation within 3 mo before PDD is most likely not associated with increased false-positive rates (OR: 0.35, p=0.26). Leukocyturia normalizes within 6 wk after the last BCG instillation, but PDD specificity is reduced up to 3 mo.
CONCLUSIONS: BCG is an important predictor for false positives in PDD (5-ALA). More than one BCG instillation within 3 mo before fluorescence cystoscopy decreases the specificity of PDD.
Предметные рубрики MeSH
Administration, IntravesicalAminolevulinic AcidAntibiotics, AntineoplasticBCG VaccineBiopsyCarcinoma, Transitional CellCystoscopyFalse Positive ReactionsFemaleHumansInflammationLeukocyte CountLogistic ModelsMaleMitomycinNeoplasm StagingNetherlandsOdds RatioPredictive Value of TestsPyuriaRetrospective StudiesRisk AssessmentRisk FactorsSensitivity and SpecificityTime FactorsTreatment OutcomeUrinary Bladder NeoplasmsUrine